These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2521422)

  • 1. Association between aluminum accumulation and cardiac hypertrophy in hemodialyzed patients.
    London GM; de Vernejoul MC; Fabiani F; Marchais S; Guerin A; Metivier F; Chappuis P; Llach F
    Am J Kidney Dis; 1989 Jan; 13(1):75-83. PubMed ID: 2521422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cortical v trabecular bone aluminum in dialyzed patients.
    Lefebvre A; Horlait S; Chappuis P; Moynot A; Masselot JP; Gueris J; de Vernejoul MC
    Am J Kidney Dis; 1988 Sep; 12(3):220-6. PubMed ID: 3414678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferoxamine test and bone disease in dialysis patients with mild aluminum accumulation.
    de Vernejoul MC; Marchais S; London G; Bielakoff J; Chappuis P; Morieux C; Llach F
    Am J Kidney Dis; 1989 Aug; 14(2):124-30. PubMed ID: 2757018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferoxamine test and PTH serum levels are useful not to recognize but to exclude aluminum-related bone disease.
    Mazzaferro S; Coen G; Ballanti P; Costantini S; Bondatti F; Giordano R; Manni M; Pasquali M; Perruzza I; Sardella D
    Nephron; 1992; 61(2):151-7. PubMed ID: 1630538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population.
    Andress DL; Maloney NA; Endres DB; Sherrard DJ
    J Bone Miner Res; 1986 Oct; 1(5):391-8. PubMed ID: 3503554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of desferrioxamine infusion on red blood cell aluminum.
    Umeda M; Umimoto K; Tsurusaki K; Izumi N; Kishimoto T; Maekawa M
    ASAIO Trans; 1988; 34(3):297-9. PubMed ID: 3196524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
    Nakazawa R
    Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
    Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG
    Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aluminum osteopathy.
    Cournot-Witmer G
    Contrib Nephrol; 1984; 38():59-64. PubMed ID: 6713901
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis.
    Randon RB; Rohde LE; Comerlato L; Ribeiro JP; Manfro RC
    Braz J Med Biol Res; 2005 Sep; 38(9):1409-16. PubMed ID: 16138225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients.
    Pei Y; Hercz G; Greenwood C; Sherrard D; Segre G; Manuel A; Saiphoo C; Fenton S
    Kidney Int; 1992 May; 41(5):1374-82. PubMed ID: 1614052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for a toxic effect of aluminum on osteoblasts: a histomorphometric study in hemodialysis patients with aplastic bone disease.
    Parisien M; Charhon SA; Arlot M; Mainetti E; Chavassieux P; Chapuy MC; Meunier PJ
    J Bone Miner Res; 1988 Jun; 3(3):259-67. PubMed ID: 3213621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bone disorders in children with chronic renal insufficiency exposed to high ingestion of aluminum].
    Gordillo-Paniagua G; Valencia-Mayoral P; Mercado L; Medina-Mercado M
    Bol Med Hosp Infant Mex; 1990 May; 47(5):336-41. PubMed ID: 2390188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone aluminum accumulation in hemodialysis patients: a longitudinal perspective.
    Kopp JB; Andress DL; Maloney NA; Sherrard DJ
    Am J Kidney Dis; 1988 Sep; 12(3):214-9. PubMed ID: 3414677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease.
    Felsenfeld AJ; Rodriguez M; Coleman M; Ross D; Llach F
    Kidney Int; 1989 Jun; 35(6):1371-8. PubMed ID: 2770115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Aluminum concentration in blood of hemodialysis patients and its clinical importance].
    Skarupskiene I; Kuzminskis V; Abdrachmanovas O; Ryselis S; Smalinskiene A; Naginiene R
    Medicina (Kaunas); 2003; 39 Suppl 1():104-8. PubMed ID: 12761430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.